- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01117623
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
November 16, 2015 updated by: Bayer
Open Label, Phase I Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAY73-4506 in Patients With Advanced Malignancies
Continuous dosing of BAY73-4506 in patients with advanced cancer
Study Overview
Status
Completed
Conditions
Intervention / Treatment
- Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg
- Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg
- Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg
- Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg
- Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg
- Drug: HCC Child-Pugh A expansion cohort: Regorafenib 100 mg
- Drug: HCC Child-Pugh B expansion cohort: Regorafenib 100 mg
- Drug: NSCLC expansion cohort: Regorafenib 100 mg
Study Type
Interventional
Enrollment (Actual)
86
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
-
-
Colorado
-
Aurora, Colorado, United States, 80045
-
-
Texas
-
Houston, Texas, United States, 77030
-
San Antonio, Texas, United States, 78229
-
San Antonio, Texas, United States, 78229-3307
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years
- Patients with advanced, histologically or cytologically confirmed solid tumors, malignant lymphomas, or multiple myeloma refractory to any standard therapy
- Radiographical, hematological or clinically evaluable tumor
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
- Life expectancy of at least 12 weeks
Adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements:
- Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN)
- Signed informed consent must be obtained prior to any study specific procedures
Exclusion Criteria:
- History of cardiac disease: congestive heart failure (CHF) > New York Heart Association (NYHA) Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; new onset angina within 3 months or unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)
- Uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg and/or diastolic blood pressure > 90 mmHg, despite optimal medical management
- History of HIV infection or chronic hepatitis B or C
- Active clinically serious infections (> Grade 2 NCI Common Terminology Criteria for Adverse Events v3.0)
- Symptomatic metastatic brain or meningeal tumors unless the patient is > 6 months from definitive therapy, has no evidence of tumor growth on an imaging study within 2 weeks prior to study entry and is clinically stable with respect to the tumor at the time of study entry. Patients with brain metastases must not be undergoing acute steroid therapy or steroid taper (chronic steroid therapy is acceptable provided that the dose is stable for one month prior to and following screening radiographic studies)
- Substance abuse, medical, psychological or social conditions that may interfere with the patient178s participation in the study or evaluation of the study results
- Radiotherapy to the target lesions within 3 weeks prior to Day 1, Cycle 1 (first dose of study drug). (Palliative radiotherapy will be allowed). Radiotherapy to the target lesions during study will be regarded as progressive disease
- Previous or concurrent cancer which is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis and T1] or any cancer curatively treated > 3 years prior to study entry.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm 1
|
Participants in the dose-escalation cohort received a single 20 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment.
On Day 3, once-daily continuous dosing with 20 mg oral co-precipitate (CP) tablets was initiated.
A cycle was defined as 21 days.
For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
|
EXPERIMENTAL: Arm 2
|
Participants in the dose-escalation cohort received a single 40 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment.
On Day 3, once-daily continuous dosing with 40 mg oral CP tablets was initiated.
A cycle was defined as 21 days.
For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
|
EXPERIMENTAL: Arm 3
|
Participants in the dose-escalation cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment.
On Day 3, once-daily continuous dosing with 100 mg oral CP tablets was initiated.
A cycle was defined as 21 days.
For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
|
EXPERIMENTAL: Arm 4
|
Participants in the dose-escalation cohort received a single 120 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment.
On Day 3, once-daily continuous dosing with 120 mg oral CP tablets was initiated.
A cycle was defined as 21 days.
For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
|
EXPERIMENTAL: Arm 5
|
Participants in the dose-escalation cohort received a single 140 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment.
On Day 3, once-daily continuous dosing with 140 mg oral CP tablets was initiated.
A cycle was defined as 21 days.
For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
|
EXPERIMENTAL: Arm 6
|
Hepatocellular carcinoma (HCC) Participants with Child Pugh A in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment.
On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated.
A cycle was defined as 21 days.
For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
|
EXPERIMENTAL: Arm 7
|
Hepatocellular carcinoma (HCC) Participants with Child Pugh B in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment.
On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated.
A cycle was defined as 21 days.
For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
|
EXPERIMENTAL: Arm 8
|
Non-small cell lung cancer (NSCLC) participants in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment.
On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated.
A cycle was defined as 21 days.
For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD)
Time Frame: Within first 4 weeks of treatment
|
The MTD was defined as the highest dose level, which could be given to 6 participants such that no more than 1 participant (less than 33%) experienced a dose-limiting toxicity (DLT).
|
Within first 4 weeks of treatment
|
Maximum Observed Plasma Concentration After Single Dose Administration (Cmax)
Time Frame: Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose
|
Cmax refers to the highest measured drug concentration, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
|
Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose
|
Area Under the Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose (AUC)
Time Frame: Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose
|
The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
|
Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose
|
Cmax at Steady State During a Dosing Interval (Cmax,ss)
Time Frame: Blood samples were collected at on Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose.
|
Cmax,ss refers to the highest measured drug concentration, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample, after multiple dose administration and after a steady state concentration has been reached.
|
Blood samples were collected at on Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose.
|
AUC From Time 0 to 24 Hours at Steady State(AUC(0-24),ss)
Time Frame: Blood samples were collected on Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose.
|
AUC(0-24),ss is a measure of systemic drug exposure over 24 hours, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample, after multiple dose administration and after a steady state concentration has been reached.
|
Blood samples were collected on Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC From Time 0 to the Last Data Point > Lower Limit of Quantification (LLOQ) (AUC(0-tlast))
Time Frame: Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose
|
The AUC(0-tlast) is a measure of systemic drug exposure from time 0 up to the time point at which the last measurable drug could be detectable, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
|
Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose
|
Area Under the Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose Divided by Dose (AUC/D)
Time Frame: Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose
|
The AUC/D is a measure of systemic drug exposure (AUC) after the first single dose, which is then divided by that dose.
It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
|
Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose
|
Maximum Observed Plasma Concentration After Single Dose Administration Divided by Dose (Cmax/D)
Time Frame: Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose
|
Cmax/D refers to the highest measured drug concentration after a single dose administration, which is then divided by the administered dose.
It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
|
Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose
|
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time Frame: Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose.
|
Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax).
It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
|
Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose.
|
Half-life Associated With the Terminal Slope (T1/2)
Time Frame: Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose.
|
T1/2 is the period of time required for the concentration or amount of drug in the body to be reduced to exactly one-half of a given concentration or amount.
It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
|
Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose.
|
Cmax at Steady State During a Dosing Interval Divided by Dose (Cmax,ss/D)
Time Frame: Blood samples were collected at on Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
|
Cmax,ss/D refers to the highest measured drug concentration after multiple dose administration and after a steady state concentration has been reached, which is then divided by the administered dose.
It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
|
Blood samples were collected at on Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
|
AUC From Time 0 to 24 Hours at Steady State Divided by Dose (AUC(0-24)ss/D)
Time Frame: Blood samples were collected on Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
|
AUC(0-24)ss/D is a measure of systemic drug exposure (AUC) over 24 hours after multiple dose administration and after a steady state concentration has been reached, which is then divided by the administered dose.
It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
|
Blood samples were collected on Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
|
Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax,ss)
Time Frame: Blood samples were collected on Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
|
Tmax,ss refers to the time after multiple dose administration and after a steady state concentration has been reached when a drug attains its highest measurable concentration (Cmax).
It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
|
Blood samples were collected on Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
|
Ratio of Cmax,ss/Cmax (RACmax)
Time Frame: Blood samples were collected on Cycle 1, Day 1 and Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
|
RACmax is the ratio of the highest drug concentration at steady state to the highest drug concentration after single dose administration.
It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
|
Blood samples were collected on Cycle 1, Day 1 and Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
|
Ratio of Cmin,ss/Cmin (RACmin)
Time Frame: Blood samples were collected on Cycle 1, Day 1 and Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
|
RACmin is the ratio of the lowest drug concentration at steady state to the lowest drug concentration after single dose administration.
It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
|
Blood samples were collected on Cycle 1, Day 1 and Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
|
Ratio of AUCt,ss/AUCt (RAAUC)
Time Frame: Blood samples were collected on Cycle 1, Day 1 and Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
|
RAAUC is the ratio of the measure of systemic drug exposure over a specific dosing interval at steady state to the measure of systemic drug exposure over a specific dosing interval after single dose administration.
It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
|
Blood samples were collected on Cycle 1, Day 1 and Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
|
Ratio of AUCt,ss/AUC (RLIN)
Time Frame: Blood samples were collected on Cycle 1, Day 1 and Cycle 2, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
|
RLIN is the ratio of the measure of systemic drug exposure at steady state to the measure of systemic drug exposure after single dose administration.
It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
|
Blood samples were collected on Cycle 1, Day 1 and Cycle 2, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
|
Biomarker Vascular Endothelial Growth Factor (VEGF) Plasma Levels
Time Frame: No data obtained
|
The analysis of Biomarker VEGF plasma levels is not done
|
No data obtained
|
Biomarker Soluble Vascular Endothelial Growth Factor Receptor 2 (sCEGFR-2) Plasma Levels
Time Frame: No data obtained
|
The analysis of Biomarker sCEGFR-2 plasma levels is not done.
|
No data obtained
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Progression in Dose Escalation Cohort
Time Frame: From the screening visit of the first participant until the last evaluation of the final participant over 6 years later, assessed at the screening visit, end of cycle 2, end of each even cycle and during the final visit (end of treatment)
|
Tumor progression evaluates changes in a tumor or tumors over time due to worsening of disease.
Measurements and observations of the tumor status were performed before, during and after treatment.
Progression for solid tumors was evaluated based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.0) criteria.
Tumor dimensions were measured in millimeters and the longest diameter (LD) was recorded for up to 5 lesions per organ and 10 lesions total.
A sum of the LD for all target lesions was recorded.
The use of a 20% increase in the sum of LD of target lesions from the smallest sum or appearance of a new lesion was assessed as progression of disease.
|
From the screening visit of the first participant until the last evaluation of the final participant over 6 years later, assessed at the screening visit, end of cycle 2, end of each even cycle and during the final visit (end of treatment)
|
Tumor Progression in Expansion Cohort
Time Frame: From the screening visit of the first participant until the last evaluation of the final participant over 6 years later, assessed at the screening visit, end of cycle 2, end of each even cycle and during the final visit (end of treatment)
|
Tumor progression evaluates changes in a tumor or tumors over time due to worsening of disease.
Measurements and observations of the tumor status were performed before, during and after treatment.
Tumor progression evaluates changes in a tumor or tumors over time due to worsening of disease.
Measurements and observations of the tumor status were performed before, during and after treatment.
Progression for solid tumors was evaluated based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.0) criteria.
Tumor dimensions were measured in millimeters and the longest diameter (LD) was recorded for up to 5 lesions per organ and 10 lesions total.
A sum of the LD for all target lesions was recorded.
The use of a 20% increase in the sum of LD of target lesions from the smallest sum or appearance of a new lesion was assessed as progression of disease.
|
From the screening visit of the first participant until the last evaluation of the final participant over 6 years later, assessed at the screening visit, end of cycle 2, end of each even cycle and during the final visit (end of treatment)
|
Tumor Response in Dose Escalation Cohort
Time Frame: From the screening visit of the first participant until the last evaluation of the final participant over 6 years later, assessed at the screening visit, end of cycle 2, end of each even cycle and during the final visit (end of treatment)
|
Tumor Response (= Best Overall Response) of a participant was defined as the best tumor response (Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes, SD was defined as steady state of disease, PD was defined as an increase of at least 20% in the sum of tumor lesions sizes.
|
From the screening visit of the first participant until the last evaluation of the final participant over 6 years later, assessed at the screening visit, end of cycle 2, end of each even cycle and during the final visit (end of treatment)
|
Tumor Response in Expansion Cohort
Time Frame: From the screening visit of the first participant until the last evaluation of the final participant over 6 years later, assessed at the screening visit, end of cycle 2, end of each even cycle and during the final visit (end of treatment)
|
Tumor Response (= Best Overall Response) of a participant was defined as the best tumor response (Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes, SD was defined as steady state of disease, PD was defined as an increase of at least 20% in the sum of tumor lesions sizes.
|
From the screening visit of the first participant until the last evaluation of the final participant over 6 years later, assessed at the screening visit, end of cycle 2, end of each even cycle and during the final visit (end of treatment)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2007
Primary Completion (ACTUAL)
November 1, 2013
Study Completion (ACTUAL)
November 1, 2013
Study Registration Dates
First Submitted
February 11, 2010
First Submitted That Met QC Criteria
May 4, 2010
First Posted (ESTIMATE)
May 5, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
November 18, 2015
Last Update Submitted That Met QC Criteria
November 16, 2015
Last Verified
November 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11651
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasm
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Advanced Malignant NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid NeoplasmUnited States, Canada
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
Ronald LevyBristol-Myers SquibbCompletedAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Extracranial Solid NeoplasmUnited States
-
Massachusetts General HospitalRecruitingMalignant Neoplasm | Benign NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Refractory NeoplasmUnited States
Clinical Trials on Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg
-
BayerCompletedColorectal NeoplasmsKorea, Republic of
-
BayerCompleted
-
BayerCompletedColorectal NeoplasmsAustria
-
BayerCompletedPharmacokinetics | Dietary FatsUnited States
-
BayerCompleted
-
BayerCompletedNeoplasmsCanada, United States
-
BayerCompletedNeoplasmsHong Kong, Singapore
-
BayerCompletedMetastatic Colorectal CancerIndia